<div id="readability-page-1"><p>HBW Advisory Services LLC boosted its holdings in shares of  Eli Lilly and Company (NYSE:LLY - Free Report) by 27.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 2,107 shares of the company's stock after buying an additional 459 shares during the period. HBW Advisory Services LLC's holdings in Eli Lilly and Company were worth $1,643,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li></ul><p>A number of other hedge funds have also modified their holdings of LLY. Brighton Jones LLC increased its holdings in shares of  Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares during the period.  Revolve Wealth Partners LLC grew its holdings in  Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after acquiring an additional 40 shares during the period.  Orion Capital Management LLC grew its holdings in  Eli Lilly and Company by 2.5% during the fourth quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock worth $1,243,000 after acquiring an additional 40 shares during the period.  Bank Pictet &amp; Cie Europe AG grew its holdings in  Eli Lilly and Company by 4.1% during the fourth quarter. Bank Pictet &amp; Cie Europe AG now owns 64,758 shares of the company's stock worth $49,993,000 after acquiring an additional 2,568 shares during the period.  Finally, Breed s Hill Capital LLC grew its holdings in  Eli Lilly and Company by 212.0% during the fourth quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock worth $1,101,000 after acquiring an additional 969 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds. </p><h2>Eli Lilly and Company Stock Performance</h2><p>Shares of Eli Lilly and Company stock opened at $754.90 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $942.35. The company has a market cap of $714.48 billion, a price-to-earnings ratio of 49.34, a PEG ratio of 1.05 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business's 50 day moving average price is $741.03 and its 200 day moving average price is $776.40. </p><ul><li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li></ul><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the business posted $3.92 earnings per share. The firm's revenue was up 37.6% compared to the same quarter last year.  Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts predict that  Eli Lilly and Company will post 23.48 EPS for the current year. </p><h2>Eli Lilly and Company Announces Dividend</h2><p>The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were given a dividend of $1.50 per share. The ex-dividend date was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Ozempic Boom: Hims &amp; Eli Lilly Lead Healthcare Bets</li></ul><p>Several research firms recently commented on LLY. Cantor Fitzgerald dropped their target price on Eli Lilly and Company from $975.00 to $825.00 and set an &#34;overweight&#34; rating on the stock in a report on Wednesday, August 13th. Erste Group Bank downgraded Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, June 5th. Hsbc Global Res upgraded Eli Lilly and Company from a &#34;moderate sell&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, August 27th. Guggenheim lowered their price target on Eli Lilly and Company from $942.00 to $875.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, August 13th. Finally, Daiwa Capital Markets downgraded Eli Lilly and Company from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. One equities research analyst  has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued  a Hold rating to the company's stock. According to MarketBeat, Eli Lilly and Company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $941.35.</p><p><b>Check Out Our Latest Stock Report on Eli Lilly and Company</b></p><h2>Insider Activity</h2><p>In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CEO David A. Ricks bought 1,632 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is owned by insiders. </p><h2>Eli Lilly and Company Profile</h2> (Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li><li>Ride the Luxury Retail Wave with These 3 High-End Brand Stocks</li><li>Why Are Stock Sectors Important to Successful Investing?</li><li>Wall Street Quietly Bets Big on These Chinese Tech Giants</li><li>Canada Bond Market Holiday: How to Invest and Trade </li><li>Meta's $600B U.S. Investment: Bearish or Bullish for Shares? </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>HBW Advisory Services LLC increased its stake in Eli Lilly and Company (NYSE: LLY) by 27.9% in Q2, now owning 2,107 shares valued at $1.64 million. Other hedge funds also raised their holdings. Eli Lilly's stock opened at $754.90, with a market cap of $714.48 billion. The company reported Q2 earnings of $6.31 EPS, exceeding estimates, and set FY 2025 guidance at 21.750-23.000 EPS. A quarterly dividend of $1.50 per share was recently paid, yielding 0.8%.</p>

Eli Lilly and Company $LLY Shares Bought by HBW Advisory Services LLC